References
Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F et al (2008) Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 93(8):1243–1246
Gollo G, Savioli G, Balocco M, Venturino C, Boeri E, Costantini M, Forni GL (2013) Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence 7:231–236
Dhirar N, Khandekar J, Bachani D, Mahto D (2016) Thalassemia major: how do we improve quality of life? Spring 5(1):1895
Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P et al (2010) Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 116(16):2875–2883
Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P (2016) Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36:47–57
Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet F-T, Nicolas C et al (2017) Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol 83(2):269–293
Fraquelli M, Cassinerio E, Roghi A, Rigamonti C, Casazza G, Colombo M et al (2010) Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol 85(8):564–568
Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A et al (2017) Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 37(3):369–376
Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F (2005) Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41(4):790–800
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Gloria Taliani has received advisory board and speaking fees from AbbVie, BMS, MSD, Roche, Janssen and Gilead. The other authors have nothing to disclose regarding funding or conflict of interest with respect to this manuscript.
Rights and permissions
About this article
Cite this article
Biliotti, E., Palazzo, D., Serani, M. et al. Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major. Ann Hematol 96, 1043–1045 (2017). https://doi.org/10.1007/s00277-017-2986-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-017-2986-x